HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
Vd0hD9C88s3vUBRU